Jon M. Steichen

This study shows that mRNA vaccines can prime and mature ultrarare HIV bnAb precursor B cells in NHPs, with improved affinity using a modified immunogen.

This paper describes the development and cGMP manufacturing of an HIV vaccine candidate for clinical trials, demonstrating scalable production and quality control.

The paper investigates how B cell affinity affects germinal center (GC) responses by showing high-affinity B cells have shorter GC residence times and lower-affinity B cells are maintained, suggesting an antibody feedback mechanism that modulates affinity and epitope spreading.

This study identifies a conserved DR motif in CDR H3 of antibodies targeting the influenza virus neuraminidase active site, suggesting a common strategy for broad protection.

Membrane-bound BG505 MD39.3 Env trimer delivered as mRNA-LNP reduced base-directed antibody responses in rabbits and macaques and elicited neutralizing antibodies, with memory B cell responses documented in macaques.

The paper presents a nanodisc platform for assembling transmembrane glycoproteins into vaccine candidates, demonstrating its utility in HIV vaccine development through structural and functional analyses.

The paper investigates how vaccine antigen delivery and adjuvant selection affect the priming of rare HIV broadly neutralizing antibody-precursor B cells in non-human primates, finding that specific dosing and adjuvant combinations enhance their detection in germinal centers.

This study visualizes lipid nanoparticle trafficking in non-human primates using PET imaging, showing distribution to muscle and draining lymph nodes with uptake by antigen-presenting cells.